NEW YORK, May 17, 2018 /PRNewswire/ — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC continues investigating potential claims on against Prothena Corporation plc (“Prothena” or the “Company”) (NASDAQ: PRTA) and certain of its officers, on behalf of shareholders who purchased Prothena securities between October 15, 2015 and April 20, 2018, inclusive (the “Class Period”). Investors are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/prta.

Bronstein, Gewirtz & Grossman, LLC

The investigation concerns whether Prothena and certain of its officers and/or directors have violated federal securities laws.

On April 23, 2018, Prothena announced that it “is discontinuing development of NEOD001, an investigational antibody that was being evaluated for the treatment of AL amyloidosis.”  The Company advised investors that “[b]ased on the results from the Phase 2b PRONTO study, which did not meet its primary or secondary endpoints, the Company asked the independent data monitoring committee (DMC) of the Phase 3 VITAL study to review a futility analysis of the ongoing VITAL study.  The DMC recommended discontinuation of the VITAL study for futility.”  On this news, Prothena’s share price fell $25.34, or 68.78%, to close at $11.50 on April 23, 2018.

If you are aware of any facts relating to this investigation, or purchased Prothena shares, you can assist this investigation by visiting the firm’s site: www.bgandg.com/prta. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz–grossman-llc-encourages-investors-who-suffered-losses-exceeding-2-000-000-investing-in-prothena-corporation-plc-prta-to-contact-the-firm-300650565.html

SOURCE Bronstein, Gewirtz & Grossman, LLC